​

ProPhase Labs (PRPH) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

PRPH Stock Forecast

ProPhase Labs (PRPH) stock forecast, based on 1 Wall Street analysts, predicts a 12-month average price target of $14.00, with a high of $14.00 and a low of $14.00. This represents a 3011.11% increase from the last price of $0.45.

- $3 $6 $9 $12 $15 High: $14 Avg: $14 Low: $14 Last Closed Price: $0.45

PRPH Stock Rating

ProPhase Labs stock's rating consensus is Hold, based on 1 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 0 Buy (0.00%), 1 Hold (100.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Hold
Total 1 0 1 Strong Sell Sell Hold Buy Strong Buy

PRPH Forecast vs Benchmarks

TypeNameUpside
StockProPhase Labs3011.11%
SectorHealthcare Stocks 25.20%
IndustrySpecialty & Generic Drug Manufacturers Stocks24.78%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$0.45$0.45$0.45
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 25------
Nov, 24-1---1
Oct, 24-1---1
Sep, 24-1---1
Aug, 24-2---2
Latest Price Target by Analysts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 17, 2022H.C. Wainwright$14.00$7.6084.21%3011.11%
Latest Upgrade/Downgrade by Analysts
DateCompanyPrevious RatingNew RatingRating Change
Jul 21, 2022Dawson JamesNeutraldowngrade

Financial Forecast

EPS Forecast

Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26
Reported$-0.21$0.41$1.17$-1.67---
Avg Forecast$-0.12$0.15$1.12$-0.73$-1.23$-0.80$1.04
High Forecast$-0.13$0.13$1.12$-0.74$-1.23$-0.80$1.04
Low Forecast$-0.10$0.17$1.12$-0.72$-1.23$-0.80$1.04
Surprise %75.00%173.33%4.46%128.77%---

Revenue Forecast

$0 $30M $60M $90M $120M $150M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26
Reported$14.51M$79.04M$122.65M$45.24M---
Avg Forecast$14.00M$62.50M$121.34M$51.60M$14.80M$50.24M$95.05M
High Forecast$12.51M$55.85M$121.34M$51.30M$14.80M$50.24M$95.05M
Low Forecast$15.49M$69.15M$121.34M$51.90M$14.80M$50.24M$95.05M
Surprise %3.66%26.47%1.08%-12.33%---

Net Income Forecast

$-100M $-70M $-40M $-10M $20M $50M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26
Reported$-2.42M$6.27M$18.46M$-28.82M---
Avg Forecast$-1.98M$1.52M$1.11M$-16.78M$-21.16M$-13.77M$17.90M
High Forecast$-2.25M$-22.81K$-685.19K$-72.73M$-21.16M$-13.77M$17.90M
Low Forecast$-1.71M$3.07M$2.90M$39.17M$-21.16M$-13.77M$17.90M
Surprise %22.30%311.52%1566.53%71.72%---

PRPH Forecast FAQ

Is ProPhase Labs stock a buy?

ProPhase Labs stock has a consensus rating of Hold, based on 1 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 0 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that ProPhase Labs is a neutral investment for most analysts.

What is ProPhase Labs's price target?

ProPhase Labs's price target, set by 1 Wall Street analysts, averages $14 over the next 12 months. The price target range spans from $14 at the low end to $14 at the high end, suggesting a potential 3011.11% change from the previous close price of $0.45.

How does ProPhase Labs stock forecast compare to the average forecast of its sector, industry, and investment themes?

ProPhase Labs stock forecast shows a 3011.11% upside, outperforming the average forecast for the healthcare stocks sector (25.20%) and outperforming the specialty & generic drug manufacturers stocks industry (24.78%).

What is the breakdown of analyst ratings for ProPhase Labs over the past three months?

  • November 2024: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • October 2024: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is ProPhase Labs’s EPS forecast?

ProPhase Labs's average annual EPS forecast for its fiscal year ending in December is -1.23 for 2024, a -26.35% decrease from the reported $-1.67 in 2023. The prediction for 2025 is $-0.8, and $1.04 for 2026.

What is ProPhase Labs’s revenue forecast?

ProPhase Labs's average annual revenue forecast for its fiscal year ending in December is $14.8M for 2024, a -67.28% decrease from the reported $45.24M in 2023. The forecast for 2025 is $50.24M, and $95.05M for 2026.

What is ProPhase Labs’s net income forecast?

For its fiscal year ending in December, ProPhase Labs's average annual net income forecast is $-21.165M for 2024, reflecting a -26.56% decrease from the reported $-28.818M in 2023. The projection for 2025 is $-13.766M, and $17.9M for 2026.